Evidence map›Paper›PMID 28825626›Full record

ArticleMolecules (Basel, Switzerland)2017

Pharmacological and Toxicological Screening of Novel Benzimidazole-Morpholine Derivatives as Dual-Acting Inhibitors.

Nafiz Öncü Can, Ulviye Acar Çevik, Begüm Nurpelin Sağlık, Yusuf Özkay, Özlem Atlı, Merve Baysal, Ümide Demir Özkay, Özgür Devrim Can

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nafiz Öncü CanDepartment of Analytical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey. nafizoc@anadolu.edu.tr.
Ulviye Acar ÇevikDoping and Narcotic Compounds Analysis Laboratory, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey. uacar@anadolu.edu.tr.
Begüm Nurpelin SağlıkDoping and Narcotic Compounds Analysis Laboratory, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey. bnsaglik@anadolu.edu.tr.
Yusuf ÖzkayDoping and Narcotic Compounds Analysis Laboratory, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey. yozkay@anadolu.edu.tr.
Özlem AtlıDepartment of Pharmaceutical Toxicology, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey. oatli@anadolu.edu.tr.
Merve BaysalDepartment of Pharmaceutical Toxicology, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey. mbaysal@anadolu.edu.tr.
Ümide Demir ÖzkayDepartment of Pharmacology, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey. udemir@anadolu.edu.tr.
Özgür Devrim CanDepartment of Pharmacology, Faculty of Pharmacy, Anadolu University, Eskişehir 26470, Turkey. ozgurdt@anadolu.edu.tr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to investigate acetylcholinesterase (AChE), monoamine oxidase A (MAO-A), monoamine oxidase B (MAO-B), cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzyme inhibitory, and antimicrobial activities of a new series of 2-(4-substituted phenyl)-1-[2-(morpholin-4-yl)ethyl]-1

Indexed as

AcetylcholinesteraseAnimalsBenzimidazolesCell LineCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase InhibitorsDose-Response Relationship, DrugEnzyme ActivationInhibitory Concentration 50MiceMolecular StructureMonoamine Oxidase InhibitorsMorpholinesProton Magnetic Resonance SpectroscopyStructure-Activity RelationshipAcetylcholinesteraseBenzimidazolesCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase InhibitorsMonoamine Oxidase InhibitorsMorpholinesAChEbenzimidazolesCOXMAOmorpholines

Identifiers

PMID28825626
PMCPMC6152416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.